• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Pre-treatment clinical assessment in head and neck cancer: United Kingdom National Multidisciplinary Guidelines.
Authors: Robson A, Sturman J, Williamson P, Conboy P, Penney S, Wood H Abstract This is the official guideline endorsed by the specialty associations involved in the care of head and neck cancer patients in the UK. This paper provides recommendations on the pre-treatment clinical assessment of patients presenting with head and neck cancer. Recommendations • Comorbidity data should be collected as it is important in the analysis of survival, quality of life and functional outcomes after treatment as well as for comparing results of different treatment regimens and different centres. (R) • Patients with hypertens...
Source: Journal of Laryngology and Otology - November 15, 2016 Category: ENT & OMF Tags: J Laryngol Otol Source Type: research

Quantitative Magnetic Particle Imaging Monitors the Transplantation, Biodistribution, and Clearance of Stem Cells In Vivo
Stem cell therapies have enormous potential for treating many debilitating diseases, including heart failure, stroke and traumatic brain injury. For maximal efficacy, these therapies require targeted cell delivery to specific tissues followed by successful cell engraftment. However, targeted delivery remains an open challenge. As one example, it is common for intravenous deliveries of mesenchymal stem cells (MSCs) to become entrapped in lung microvasculature instead of the target tissue. Hence, a robust, quantitative imaging method would be essential for developing efficacious cell therapies. Here we show that Magnetic Par...
Source: Theranostics - June 5, 2016 Category: Molecular Biology Authors: Bo Zheng, Marc P. von See, Elaine Yu, Beliz Gunel, Kuan Lu, Tandis Vazin, David V. Schaffer, Patrick W. Goodwill, Steven M. Conolly Tags: Research Paper Source Type: research

What is the best approach in a patient with a failed aortic bioprosthetic valve: transcatheter aortic valve replacement or redo aortic valve replacement?
A best evidence topic in cardiac surgery was written according to a structured protocol. The question addressed was whether transcatheter aortic valve-in-valve replacement (viv-TAVR) or redo aortic valve replacement (rAVR) is the best strategy in a patient with a degenerative bioprosthetic aortic valve. Altogether, 162 papers were found using the reported search, of which 12 represented the best evidence to answer the question. The authors, journal, date, country of publication, patient group, study type, outcomes and results of papers are tabulated. The results of the studies provided interesting results. All the studies ...
Source: Interactive CardioVascular and Thoracic Surgery - May 28, 2015 Category: Cardiovascular & Thoracic Surgery Authors: Tourmousoglou, C., Rao, V., Lalos, S., Dougenis, D. Tags: Lung - cancer, Trachea and bronchi, Congestive Heart Failure, Transplantation - heart, Valve disease, Vascular malformations Adult Cardiac Source Type: research

Effect of Preoperative Atrial Fibrillation on Clinical Outcomes After Continuous Flow-Left Ventricular Assist Device Therapy
Atrial fibrillation (AF) is the most common chronic cardiac arrhythmia, often found in patients with heart failure requiring a ventricular assist device. Our goal was to assess the effect of preoperative AF on the risk of thromboembolic (TE) events (hemolysis, stroke and/or TIA), clinical outcomes and survival in patients receiving a continuous-flow left ventricular assist device (CF-LVAD).
Source: The Journal of Heart and Lung Transplantation - April 1, 2015 Category: Transplant Surgery Authors: E. Lushaj, S. Akhter, T. Kohmoto, L. Lozonschi, M. Murray, S. Osaki Source Type: research

Temporal Differences in Adverse Event Rates in Patients Bridged With the HeartWare Left Ventricular Assist Device
Left ventricular assist devices (LVAD) have significantly improved survival and quality of life in patients with advanced heart failure. However, these devices are associated with significant adverse events (AEs), particularly bleeding, infection, stroke and right heart failure. We sought to evaluate temporal differences in AE rates in patients bridged to transplantation.
Source: The Journal of Heart and Lung Transplantation - April 1, 2015 Category: Transplant Surgery Authors: S. Maltais, K.D. Aaronson, J.J. Teuteberg, M.S. Slaughter, S.S. Najjar, V. Jeevanandam, D.T. Pham, E.C. McGee, K. Najarian, R.L. Kormos Source Type: research

Left Ventricular Assist Devices vs. the Total Artificial Heart: Which Causes More Cerebrovascular Accidents?
More recently, the continuous flow left ventricular assist devices (LVADs) have been more commonly used in patients (pts) with severe left heart failure. However, these devices also have risk for strokes, both ischemic and hemorrhagic. The Total Artificial Heart (TAH) has also been used in patients with biventricular heart failure at our single institution. Both continuous flow LVADs and TAH patients are systemically anti-coagulated with warfarin and aspirin. We sought to compare stroke rates between the LVAD patients and TAH pts.
Source: The Journal of Heart and Lung Transplantation - April 1, 2015 Category: Transplant Surgery Authors: C. Runyan, F. Arabia, L. Czer, M. Kittleson, E. Passano, F. Liou, J. Yabuno, H. Henry, D.H. Chang, J. Kobashigawa, J. Moriguchi Source Type: research

First Implantation in Man of a New Magnetically Levitated Left Ventricular Assist Device (HeartMate III)
Outcomes of heart failure patients supported by a continuous flow left ventricular assist device (LVAD) have steadily improved over the past decade due in large part to better patient selection and management 1,2. Nevertheless, adverse events such as bleeding, infection, stroke and thrombus persist and limit the overall effectiveness of this therapy. Bleeding is the most common serious adverse event that results from the extensive surgery required for implantation and blood component damage due to shear forces in the small blood flow paths of current design axial-flow and centrifugal-flow pumps.
Source: The Journal of Heart and Lung Transplantation - March 7, 2015 Category: Transplant Surgery Authors: Jan D. Schmitto, Jasmin S. Hanke, Sebastian V. Rojas, Murat Avsar, Axel Haverich Source Type: research

Blood pressure and stroke risk in left ventricular assist devices
Ischemic and hemorrhagic stroke are one of the most devastating outcomes arising from treatment of end-stage congestive heart failure with a left ventricular assist device (LVAD)1. Stroke after LVAD is associated with increased risk of mortality and is a leading cause of not qualifying for transplantation. The risk of stroke is one of many factors limiting more widespread adoption of this technology for end-stage heart failure. The risk factors for stroke in LVAD have been the subject of several studies, with recent infection2 and changes in anti-thrombotics being commonly found3.
Source: The Journal of Heart and Lung Transplantation - December 5, 2014 Category: Transplant Surgery Authors: Joshua Z. Willey Source Type: research

Extracorporeal Membrane Oxygenation: Experience In Acute Graft Failure After Heart Transplantation
ConclusionTemporary ECMO support for postoperative output failure is an acceptable option as a last resort for otherwise doomed patients with fatal graft failure after HTx. The small fraction of patients surviving, appear to have a decent long‐term prognosis.This article is protected by copyright. All rights reserved.
Source: Clinical Transplantation - April 1, 2014 Category: Transplant Surgery Authors: Sven Lehmann, Madlen Uhlemann, Christian D. Etz, Jens Garbade, Thomas Schroeder, Michael Borger, Martin Misfeld, Hartmuth B Bittner, Friedrich Wilhelm Mohr Tags: Original Article Source Type: research

Post-approval study of a highly pulsed, low-shear-rate, continuous-flow, left ventricular assist device, EVAHEART: A Japanese multicenter study using J-MACS
Conclusions: The EVAHEART device provides safe, reliable and long-term circulatory support with improved survival in commercial settings of BTT in Japan, where the transplant waiting period is much longer. Incidences of GI bleeding, hemolysis, right ventricular failure, device thrombosis and mechanical failure were extremely rare in patients on EVAHEART devices.
Source: The Journal of Heart and Lung Transplantation - March 6, 2014 Category: Transplant Surgery Authors: Satoshi Saito, Kenji Yamazaki, Tomohiro Nishinaka, Yuki Ichihara, Minoru Ono, Syunei Kyo, Takashi Nishimura, Takeshi Nakatani, Koichi Toda, Yoshiki Sawa, Ryuji Tominaga, Tadahisa Tanoue, Yoshikatsu Saiki, Yoshiro Matsui, Takahiro Takemura, Hiroshi Niinami Tags: Featured Articles Source Type: research

Incidence of increases in pump power use and associated clinical outcomes with an axial continuous-flow ventricular assist device
Left ventricular assist devices (LVADs) have been shown to improve survival in patients with end-stage heart failure. Newer-generation LVADs with continuous-flow mechanics yield lower rates of disabling stroke, infection, and need for device exchange compared with earlier pulsatile-flow devices. It has been hypothesized that an elevation in the pump power may be an early indication of device thrombosis. Our goal was to define the frequency of pump power elevations, evaluate when they happen in relation to device implantation, and determine the rate at which they precede adverse events suggestive of pump thrombosis.
Source: The Journal of Heart and Lung Transplantation - January 1, 2014 Category: Transplant Surgery Authors: Robert J. Steffen, Edward G. Soltesz, Kimberly Miracle, Sangjin Lee, Maria Mountis, Nader Moazami Tags: Research Correspondence Source Type: research

Carotid-bulb thrombus and continuous-flow left ventricular assist devices: A novel observation
The continuous-flow left ventricular assist device (LVAD) has emerged as a clinically important treatment strategy for patients with advanced-stage heart failure. However, LVADs are not without associated neurologic complications, including stroke. In one review, the incidence of stroke (both ischemic and hemorrhagic) with the HeartMate II (HM II; Thoratec, Pleasanton, CA) ranged from 2% to 18%. In another recent single-center study, the incidence was 10%. In that study, previous stroke, persistent malnutrition and inflammation, severity of heart failure and post-LVAD infections were associated with neurologic complications.
Source: The Journal of Heart and Lung Transplantation - October 28, 2013 Category: Transplant Surgery Authors: John T. Reul, George J. Reul, O.H. Frazier Tags: Research Correspondence Source Type: research

A longer waiting game: Bridging children to heart transplant with the Berlin Heart EXCOR device—the United Kingdom experience
Conclusions: BH use in the UK has allowed significant increases in the number of children with end-stage heart failure who can be successfully bridged to transplant and the length of time they can be supported. The total number of transplants has not increased.
Source: The Journal of Heart and Lung Transplantation - September 23, 2013 Category: Transplant Surgery Authors: Jane Cassidy, Troy Dominguez, Simon Haynes, Michael Burch, Richard Kirk, Aparna Hoskote, Jon Smith, Matthew Fenton, Massimo Griselli, Tain-Yen Hsia, Lee Ferguson, Carin Van Doorn, Asif Hasan, Ann Karimova Tags: Original Clinical Science Source Type: research

Diagnosis of hemolysis and device thrombosis with lactate dehydrogenase during left ventricular assist device support
Mechanical circulatory support (MCS) with a continuous-flow (CF) rotary pump is associated with low levels of hemolysis during normal pump operation. Clinically significant hemolysis can be an early sequelae of pump thrombus. Left ventricular assist device (LVAD) thrombosis may result in stroke, peripheral embolism, heart failure, device exchange, and death. The timely detection of pump thrombus remains challenging.
Source: The Journal of Heart and Lung Transplantation - August 21, 2013 Category: Transplant Surgery Authors: Palak Shah, Vivek M. Mehta, Jennifer A. Cowger, Keith D. Aaronson, Francis D. Pagani Tags: Research Correspondence Source Type: research

Chronic obstructive pulmonary disease.
Abstract The global prevalence of physiologically defined chronic obstructive pulmonary disease (COPD) in adults aged >40 yr is approximately 9-10 per cent. Recently, the Indian Study on Epidemiology of Asthma, Respiratory Symptoms and Chronic Bronchitis in Adults had shown that the overall prevalence of chronic bronchitis in adults >35 yr is 3.49 per cent. The development of COPD is multifactorial and the risk factors of COPD include genetic and environmental factors. Pathological changes in COPD are observed in central airways, small airways and alveolar space. The proposed pathogenesis of COPD includes pr...
Source: The Indian Journal of Medical Research - February 1, 2013 Category: Biomedical Science Authors: Vijayan VK Tags: Indian J Med Res Source Type: research

Pages: 1  2  3  4  5  6